Analyst Price Target is $27.67
▲ +524.53% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Eledon Pharmaceuticals in the last 3 months. The average price target is $27.67, with a high forecast of $33.00 and a low forecast of $25.00. The average price target represents a 524.53% upside from the last price of $4.43.
Current Consensus is
The current consensus among 4 contributing investment analysts is to buy stock in Eledon Pharmaceuticals.
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm's compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.